Catechol-O-Methyltransferase (COMT) gene polymorphism and breast cancer risk in young women
2001 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 85, no 6, 859-862 p.Article in journal (Refereed) Published
Oestrogen exposure has long been considered to be a main risk factor of breast cancer. More recently, interest has also focused on the possible carcinogenic influence from oestrogen metabolites, such as catechol oestrogens. O-methylation, catalysed by Catechol-O-Methyltransferase (COMT), is one pathway by which the potentially carcinogenic catechol oestrogens can be inactivated. The gene coding for COMT protein contains a single-nucleotide polymorphism (SNP), resulting in an amino acid shift Val Met, which has been shown to determine high- and low-activity configuration of the enzyme. We hypothesized that the low-activity allele, COMTMet, may be implicated in early onset breast cancer. In the present case–control study, including 126 young breast cancer patients ( 36 years) and 117 healthy female blood donors, we analysed the association between COMTMet genotype and risk of breast cancer. No significant difference in the frequency of low-/high-activity alleles was found between cases and controls, indicating that the polymorphism, as a single factor, may not contribute to breast carcinogenesis in young women.
Place, publisher, year, edition, pages
2001. Vol. 85, no 6, 859-862 p.
Catechol-O-Methyltransferase, COMT, genetic polymorphism, breast cancer, early onset, catechol oestrogens
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-24935DOI: 10.1054/bjoc.2001.2009Local ID: 9341OAI: oai:DiVA.org:liu-24935DiVA: diva2:245259